Your analysis makes good sense with clear rationality. In particular, the impact of GLP-1s on Obstructive Sleep Apnea (OSA) and subsequently on ResMed’s volumes is a core uncertainty for the years ahead. However, I remain confident that there are much more penetrations of continuous positive airway pressure (CPAP) therapy to people in developed and developing countries in particular.
Having noted the impact of GLP-1s on RMD share price, the price goes up and up as we are worrying and writing.
Looking at RSI (14 & 30 days line) technical indications, it is not in overbought territory yet.
Buy RMD now and get great upside returns in a year or two, page-62
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$34.66 |
Change
-0.100(0.29%) |
Mkt cap ! $21.25B | |||
| Open | High | Low | Value | Volume |
| $34.65 | $34.82 | $34.53 | $45.12M | 1.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $34.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $34.76 | 632 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RMD (ASX) Chart |